We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+29.23%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$852M
AUM Growth
+$402M
Cap. Flow
+$256M
Cap. Flow %
30.02%
Top 10 Hldgs %
54.49%
Holding
73
New
24
Increased
20
Reduced
15
Closed
11

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$48.3M
2
AZN icon
AstraZeneca
AZN
+$41.9M
3
GSK icon
GSK
GSK
+$32.4M
4
UTHR icon
United Therapeutics
UTHR
+$28.6M
5
AMRN
Amarin Corp
AMRN
+$25.5M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$18.5M
2
OSUR icon
OraSure Technologies
OSUR
+$11.4M
3
HSKA
Heska Corp
HSKA
+$10.3M
4
LAB icon
Standard BioTools
LAB
+$9.68M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$9.26M

Sector Composition

Rank Sector Weight
1 Healthcare 97.63%
2 Miscellaneous 2.33%
3 Financials 0.05%
4 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
51
DexCom
DXCM
$34.3B
$914K 0.11%
+9,892
New +$883K
TARA icon
52
Protara Therapeutics
TARA
$226M
$879K 0.1%
36,310
– –
IQV icon
53
IQVIA
IQV
$43.1B
$732K 0.09%
+4,085
New +$688K
A icon
54
Agilent Technologies
A
$43.4B
$590K 0.07%
+4,977
New +$551K
GOCO
55
DELISTED
GoHealth
GOCO
$405K 0.05%
1,979
+1,104
+126% +$205K
KALV
56
DELISTED
KalVista Pharmaceuticals
KALV
$359K 0.04%
18,925
-88,375
-82% -$1.52M
LCI
57
CALL
DELISTED
Lannett Company, Inc.
LCI
$354K 0.04%
15,975
-14,650
-48% -$383K
ZYME icon
58
Zymeworks
ZYME
$2.02B
$255K 0.03%
+5,405
New +$251K
MRUS
59
DELISTED
Merus
MRUS
$253K 0.03%
+14,445
New +$213K
APLS
60
DELISTED
Apellis Pharmaceuticals
APLS
$218K 0.03%
3,816
-77,451
-95% -$3.28M
CYTK icon
61
CALL
Cytokinetics
CYTK
$10B
$208K 0.02%
+10,000
New +$183K
CYH icon
62
Community Health Systems
CYH
$413M
$95.1K 0.01%
+12,805
New +$90.6K
CLDX icon
63
Celldex Therapeutics
CLDX
$3.07B
– –
-150,494
Closed -$2.23M
LAB icon
64
Standard BioTools
LAB
$252M
– –
-1,302,353
Closed -$9.68M
LQDA icon
65
Liquidia Corp
LQDA
$6.06B
– –
-182,751
Closed -$899K
MRSN
66
DELISTED
Mersana Therapeutics
MRSN
– –
-5,600
Closed -$2.61M
OSUR icon
67
OraSure Technologies
OSUR
$248M
– –
-940,412
Closed -$11.4M
SCPH
68
DELISTED
scPharmaceuticals
SCPH
– –
-65,605
Closed -$489K
SLDB icon
69
Solid Biosciences
SLDB
$1.05B
– –
-20,468
Closed -$623K
VTRS icon
70
Viatris
VTRS
$18.8B
– –
-324,951
Closed -$4.82M
MODN
71
DELISTED
MODEL N, INC.
MODN
– –
-188,967
Closed -$6.67M
TLGT
72
DELISTED
Teligent, Inc
TLGT
– –
-305,423
Closed -$220K
MNTA
73
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-98,501
Closed -$5.17M
1 2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Eversept Partners held 73 positions worth $852M, up 89% from $450M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Eversept Partners deployed $256M of net new capital in Q4 2020, opening 24 new positions and adding to 20 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 376,200 shares worth $58.8M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $18.5M trimmed.

  • Eversept Partners's largest Q4 2020 buy was Alexion Pharmaceuticals: 376,200 shares worth $58.8M.
  • Eversept Partners added most to AstraZeneca in Q4 2020, an estimated $41.9M increase.
  • Eversept Partners's biggest Q4 2020 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $18.5M.
  • Eversept Partners fully exited OraSure Technologies in Q4 2020, selling an estimated $11.4M.
  • Eversept Partners's ten largest holdings make up 54% of its $852M portfolio in Q4 2020.
  • Eversept Partners opened 24 new positions and closed 11 in Q4 2020.
  • Eversept Partners's portfolio value rose 89% quarter-over-quarter to $852M.

Based on Eversept Partners's 13F filing for Q4 2020, filed 16 Feb 2021.